IceCure Medical Ltd. (ICCM) shareholders
Close on Nov 17, 2026Market cap $2.84MP/E 0.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mr. Li Haixiang Joint filing with Epoch Partner Investments Limited (45.80%) | 35,846,597 | 45.80% | 13D (active) amendment | Mar 17, 2026 |
| Epoch Partner Investments Limited | 25,846,597 | 52.20% | 13G (passive) amendment | Sep 30, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 300,332 | 9.99% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ICCM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 34,885 | 0.05% | $169.54K | New | 0.00% |
| Scientech Research LLC | 32,696 | 0.04% | $158.90K | New | 0.13% |
| Gunderson Capital Management Inc. | 20,000 | 0.03% | $3.03K | +19,333 | 0.00% |
| UBS Group AG | 17,093 | 0.02% | $83.07K | +11,954 | 0.00% |
| Hrt Financial LP | 15,151 | 0.02% | $73.00K | +13,564 | 0.00% |
| JPMorgan Chase & Co | 5,950 | 0.01% | $31.30K | +5,752 | 0.00% |
| Morgan Stanley | 4,334 | 0.01% | $21.06K | +3,767 | 0.00% |
| Kingdom Financial Group LLC. | 533 | 0.00% | $2.59K | – | 0.00% |
| SBI Securities Co., Ltd. | 451 | 0.00% | $2.19K | +451 | 0.00% |
| Avion Wealth | 195 | 0.00% | $0 | – | 0.00% |
| Bartlett & Co. Wealth Management LLC | 8 | 0.00% | $39 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 11 | 0M | 0.2% | 2 / 6 | 0 / 9 | 0M | 0M |
| Q1 2026 | 18 | 0M | 0.1% | 5 / 3 | 0 / 6 | 0M | 0M |
| Q4 2025 | 19 | 0M | 0.0% | 5 / 2 | 3 / 3 | 0M | 0M |
| Q3 2025 | 17 | 0M | 0.0% | 1 / 8 | 2 / 2 | 0M | 0M |
| Q2 2025 | 18 | 0M | 0.0% | 6 / 4 | 0 / 2 | 0M | 0M |
| Q1 2025 | 14 | 0M | 0.0% | 4 / 0 | 2 / 3 | 0M | 0M |
| Q4 2024 | 13 | 0M | 0.0% | 3 / 2 | 2 / 5 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.0% | 4 / 0 | 2 / 3 | 0M | 0M |
| Q2 2024 | 14 | 0M | 0.0% | 5 / 2 | 1 / 3 | 0M | 0M |
| Q1 2024 | 12 | 0M | 0.0% | 4 / 2 | 2 / 9 | 0M | 0M |
| Q4 2023 | 17 | 0M | 0.0% | 7 / 3 | 3 / 2 | 0M | 0M |
| Q3 2023 | 12 | 0M | 0.0% | 5 / 3 | 2 / 5 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eyal Shamir | Chief Executive Officer, Director | 431,281 | 0.59% | Nov 2, 2026 |
| Shad Good | VP, Sales for North America | 136,698 | 0.19% | Aug 17, 2026 |
| Shay Levav | Chief Operating Officer | 146,303 | 0.20% | Aug 17, 2026 |
| Tlalit Bussi Tel-Tzure | VP, BD & Global Marketing | 106,518 | 0.15% | Aug 17, 2026 |
| Meir Peleg | Chief Financial Officer | 194,816 | 0.27% | Aug 17, 2026 |
| Merav Nir Dotan | VP, Human Resources | 76,168 | 0.10% | Aug 17, 2026 |
| Naum Muchnik | VP, R&D & Engineering | 118,621 | 0.16% | May 18, 2026 |
| Ronen Tsimerman | Chief Financial Officer | 177,949 | 0.24% | May 18, 2026 |
| Ron Mayron | Director | 176,464 | 0.24% | Nov 2, 2026 |
| David Salton | Director | – | – | Aug 17, 2026 |
| Vincent Chun Hung Chan | Director | – | – | Aug 17, 2026 |
| Sharon Levita | Director | – | – | Mar 25, 2026 |
| Yonatan Malca | Director | – | – | Mar 25, 2026 |
| Yang Huang | Director | 111,468 | 0.15% | Mar 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eyal Shamir Chief Executive Officer, Director | Nov 2, 2026 | Award | +404,901 | – | – | 431,281 |
| Ron Mayron Director | Nov 2, 2026 | Award | +166,577 | – | – | 176,464 |
| Meir Peleg Chief Financial Officer | Aug 14, 2026 | Award | +181,483 | – | – | 194,816 |
| Tlalit Bussi Tel-Tzure VP, BD & Global Marketing | Aug 14, 2026 | Award | +101,483 | – | – | 106,518 |
| Shay Levav Chief Operating Officer | Aug 14, 2026 | Award | +141,483 | – | – | 146,303 |
| Shad Good VP, Sales for North America | Aug 14, 2026 | Award | +131,483 | – | – | 136,698 |
| Merav Nir Dotan VP, Human Resources | Aug 14, 2026 | Award | +73,890 | – | – | 76,168 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IceCure Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,282 shares on Oct 1, 2026 over the last 90 days.
See a number that looks wrong?